Advanced search
Publication Cover
Renal Failure Volume 42, 2020 - Issue 1
Submit an article Journal homepage
1,060
Views
0
CrossRef citations to date
0
Altmetric
Brief Report

Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient

Jin Chena School of Medicine, University of Electronic Science and Technology of China;b Department of Nephrology, Sichuan Provincial People’s HospitalView further author information
,
Yi Lia School of Medicine, University of Electronic Science and Technology of China;b Department of Nephrology, Sichuan Provincial People’s HospitalView further author information
,
Guisen Lia School of Medicine, University of Electronic Science and Technology of China;b Department of Nephrology, Sichuan Provincial People’s HospitalORCID Iconhttps://orcid.org/0000-0003-1970-9979View further author information
ORCID Icon &
Lei Pua School of Medicine, University of Electronic Science and Technology of China;b Department of Nephrology, Sichuan Provincial People’s HospitalCorrespondence[email protected]
View further author information
Pages 377-380 | Received 10 Dec 2019, Accepted 29 Mar 2020, Published online: 17 Apr 2020

References

  • Kidney Disease: Improving Global Outcomes Hepatitis CWG Kdigo 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis c in chronic kidney disease. Kidney Int Suppl. 2011;8:91–165.
  • Barsoum RS, William EA, Khalil SS. Hepatitis c and kidney disease: A narrative review. J Adv Res. 2017;8(2):113–130.
  • Goodkin DA, Bieber B, Jadoul M, et al. Mortality, hospitalization, and quality of life among patients with hepatitis c infection on hemodialysis. CJASN. 2017;12(2):287–297.
  • Li P-T, Chow KM, Van de Luijtgaarden MWM, et al. Changes in the worldwide epidemiology of peritoneal dialysis. Nat Rev Nephrol. 2017;13(2):90–103.
  • Vidales-Braz B, da Silva N, Lobato R, et al. Detection of hepatitis c virus in patients with terminal renal disease undergoing dialysis in southern brazil: Prevalence, risk factors, genotypes, and viral load dynamics in hemodialysis patients. Virol J. 2015;12(1):8.
  • Zineb Lioussfi ZE, Radoui A, Rhou H, et al. Viral hepatitis c and b among dialysis patients at the rabat university hospital- prevalence and risk factors. Saudi J Kidney Dis Transpl. 2014;25(3):672–679.
  • Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis c virus genotype 1 infection and stage 4–5 chronic kidney disease (the c-surfer study): a combination phase 3 study. Lancet. 2015;386(10003):1537–1545.
  • Ogawa E, Furusyo N, Azuma K, et al. Elbasvir plus grazoprevir for patients with chronic hepatitis c genotype 1: a multicenter, real-world cohort study focusing on chronic kidney disease. Antiviral Res. 2018;159:143–152.
  • Reddy KR, Roth D, Bruchfeld A, et al. Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis c virus infection and pre-existing renal disease. Hepatol Res. 2017;47(12):1340–1345.
  • Choi DT, Puenpatom A, Yu X, et al. Effectiveness of elbasvir/grazoprevir in patients with hepatitis c virus genotype 1 infection and chronic kidney disease in the united states veterans population. Antiviral Res. 2020;174:104698.
  • Simmons B, Saleem J, Heath K, et al. Long-term treatment outcomes of patients infected with hepatitis c virus: A systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis. 2015;61(5):730–740.
  • Söderholm J, Millbourn C, Büsch K, et al. Higher risk of renal disease in chronic hepatitis c patients: Antiviral therapy survival benefit in patients on hemodialysis. J Hepatol. 2018;68(5):904–911.
  • Fabrizi F, Aghemo A, Messa P. Hepatitis c treatment in patients with kidney disease. Kidney Int. 2013;84(5):874–879.
  • Aggarwal A, Yoo ER, Perumpail RB, et al. Sofosbuvir use in the setting of end-stage renal disease: A single center experience. J Clin Transl Hepatol. 2017;5(06):23–26.
  • Borgia SM, Dearden J, Yoshida EM, et al. Sofosbuvir/velpatasvir for 12 weeks in hepatitis c virus-infected patients with end-stage renal disease undergoing dialysis. J Hepatol. 2019;71(4):660–665.
  • Shuster DL, Menon RM, Ding B, et al. Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic hcv infection: Pharmacokinetic analysis of the phase 3 ruby-i and ruby-ii trials. Eur J Clin Pharmacol. 2019;75(2):207–216.
  • Stark JE, Cole J. Successful treatment of chronic hepatitis c virus infection in a patient receiving daily peritoneal dialysis. Am J Health-System Pharm. 2017;74(19):1541–1544.
  • Londoño M-C, Riveiro-Barciela M, Ahumada A, et al. Effectiveness, safety/tolerability of obv/ptv/r ± dsv in patients with hcv genotype 1 or 4 with/without hiv-1 co-infection, chronic kidney disease (ckd) stage iiib-v and dialysis in spanish clinical practice – vie-kind study. PLoS One. 2019;14(9):e0221567.
  • Caro L, Wenning L, Feng HP, et al. Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment. Eur J Clin Pharmacol. 2019;75(5):665–675.
  • Gamal N, Andreone P. Grazoprevir/elbasvir fixed-dose combination for hepatitis c. Drugs Today. 2016;52(7):377.
  • Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir–elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis c virus genotype 1, 4, or 6 infection. Ann Intern Med. 2015;163(1):1.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.